AilsynBio and Dong-E-E-Jiao Sign Project Cooperation Agreement Empowering Traditional Medicine with AI to Open a New Chapter in the Health Industry
- Written by Media Outreach
The ceremony brought together influential leaders and experts from industry, academia, and research sectors, including senior representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation (HKSTP), and The University of Hong Kong (HKU), to witness this significant milestone.
Dr. Bo Chen, Chief Scientific Officer of China Resources Pharmaceutical, noted:
"This collaboration with Dong-E-E-Jiao and AilsynBio is a key initiative for China Resources Pharmaceutical in advancing the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of 'AI + TCM' between Mainland China and Hong Kong. We look forward to leveraging scientific research and industrial resources from both regions to overcome the challenges of TCM's mechanisms of action and to pave an innovative path for TCM to evolve from empirical medicine to evidence-based medicine."
Mr. Liang Zheng, Vice President of Dong-E-E-Jiao, stated:
"As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women's health, helping Dong-E-E-Jiao accelerate into a new stage of 'reshaping TCM wisdom through technological innovation.'"
Mr. Pierre Wang, Managing Director of HKU Versitech Limited, stated:
"HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of Hong Kong's top-tier academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company's rapid international growth and its mission to scale cutting-edge biotechnology globally."
Looking ahead, the two parties will focus on three key collaborative directions:
- Advancing AI-driven innovation: Leveraging AilsynBio's AI drug discovery platform to accelerate biopharmaceutical R&D processes.
- Launching specialized research: Engaging in in-depth cooperation on the "Premature Ovarian Insufficiency (POI)" research project.
- Promoting cross-border fusion: Exploring the integration of biotechnology, AI, and traditional medicine to jointly create a new paradigm for the health industry.
AilsynBio stated that this cooperation is not only a combination of cutting-edge technology and traditional medicine, but also a strategic layout for future healthcare innovation. By leveraging AI technology, the partnership aims to inject technological vitality into traditional medicine for the benefit of more patients.
Hashtag: #AilsynBio #昂心生物
The issuer is solely responsible for the content of this announcement.
